Detailed Narrative
Strategic Pivot to Specialty CDMO
OneSource was formed to simplify supply chains for customers by bringing multiple capabilities under one roof, creating India's first specialty pharma CDMO. The company has evolved from having no common customers across service offerings to having many customers utilizing multiple modalities. Management highlights that this 'one-stop-shop' approach is already resulting in a higher share of customer wallets and increased traction across biologics, sterile injectables, and soft gelatins.
GLP-1 and Cartridge Capacity Expansion
The company is making a massive bet on the GLP-1 market, planning to increase its cartridge capacity from 40 million to 220 million units by 2028. They currently have 20 active customers in the GLP-1 space, including some of the 'who's who' of the global generic industry. Management estimates they could eventually capture up to one-third of the total generic market for GLP-1 fill-finish, leveraging their early-mover advantage and specialized isolator-based technology.
Financial Trajectory and Margin Expansion
Q3 FY25 saw a significant jump in EBITDA margins to 36%, up from the combined margins of the previous two quarters. This expansion is attributed to the increasing traction of the high-margin biologics and drug-device combination business. Management has set a medium-term target of achieving a 40% EBITDA margin as the business shifts from pre-approval (MSA) revenue to commercial (CSA) revenue, which is expected to reach an 80-20 mix in favor of commercial sales by FY27.
Balance Sheet Optimization and Debt Reduction
Following the NCLT process and listing, the company is focused on cleaning up its balance sheet. It raised ₹801 crores during the quarter, using half to retire high-cost debt and reduce guarantees. The company aims to be completely debt-free by the end of FY27, down from a current net debt of ₹581 crores. Management is also actively working with advisors to address the ₹5,000 crore goodwill sitting on the balance sheet to improve future ROCE.
Biologics and Integrated Manufacturing
OneSource differentiates itself with an integrated biologics site that handles both drug substance and drug product in one location. They have already onboarded their first innovator customer in the microbial area and are seeing increased RFPs from American, Japanese, and biotech companies. While biologics is a long-gestation business, management expects significant commercial revenue to begin contributing in 3-4 years, providing a long-term growth tailwind beyond current guidance.